Anika (ANIK) Discloses FDA Seeking Added Info on Monovisc

Article Stock Quotes (1) Comments (0)

In a Form 8-K after the close Thursday, Anika Therapeutics (Nasdaq: ANIK) disclosed the FDA requested additional information in order to pass judgment on the appeal of its Monovisc PMA. The company plans to submit that information within two months and was promised a timely review and decision by the FDA.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• Cardiovascular Systems (CSII) ORBIT II Trial Met Endpoints
• News Corp (NWSA) Splits In Two; Announces $500M Buyback Plan

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?